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ABSTRACT
Introduction: Calls for an alternative to
valproic acid (VPA) as drug of choice for
idiopathic generalized epilepsies (IGEs) have
intensified since the recent International
League Against Epilepsy recommendation that
the drug should not be administered to women
of childbearing age. Zonisamide (ZNS), a
third-generation antiepileptic drug, has proven
effective in generalized seizures and could be
considered an alternative to VPA in this
population.
Objectives: The present study was designed to
examine possible differences in cognitive profile
between ZNS and VPA as monotherapy in
patients with IGE in real-life settings.
Methods: We conducted a comparative,
descriptive, observational, retrospective cohort
study in two groups of patients diagnosed with
IGE treated with ZNS C200 mg/day or VPA
C1000 mg/day as stable monotherapy for at
least the previous 6 months. We used specific
neuropsychological tests for short- and
long-term mnemonic functions, working
memory, visuospatial speed, attention and
processing speed, verbal fluency, executive
functions, visual perception, abstraction,
anxiety, depression, and apathy.
Results: We included 16 patients in the study:
eight in the VPA and eight in the ZNS group.
Significantly superior mean scores were
obtained by the VPA group in working
memory (Forward Digits test) and by the ZNS
group in execution time for the Rey–Osterrieth
complex figure test. No statistically significant
differences were found between the groups in
the remaining tests.
Conclusion: Zonisamide as monotherapy has a
similar cognitive profile to that of VPA in
patients with IGE. The final treatment
selection setting should be individualized. ZNS
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may be a reasonable alternative to VPA in some
cases in this population.




The so-called third-generation antiepileptic
drugs (AEDs) have not been able to modify the
natural history of the disease, but they have
demonstrated superior pharmacokinetic,
pharmacodynamic, and adverse-effect profiles,
improving the quality of life of patients with
epilepsy [1, 2]. This improvement is largely
attributable to the reduced cognitive or
psychiatric adverse effects, which play a key
role in the quality of life of patients with
epilepsy [3].
Zonisamide (ZNS), a third-generation AED,
was approved for clinical use in Japan in 1989,
by the US Food and Drug Administration in
2000, and by the European Medicines Agency in
2005 [4]. The availability of a ZNS monotherapy
regimen since 2012 in the European Union has
renewed interest in this drug and its benefits,
including its wide spectrum of action. Besides
its accredited usefulness in the treatment of
partial seizures, various studies have
demonstrated its effectiveness in generalized
seizures [5–7]. Zonisamide achieved a 50%
reduction in these seizures in 72.4%–82% of
patients and freedom from seizures in[50% of
patients with different types of idiopathic
generalized epilepsy (IGE) [4]. These data
suggest that ZNS may be an alternative to
valproic acid (VPA), which is considered the
treatment of choice for this type of epilepsy in
most current practice guidelines.
Few data have been published on the cognitive
adverse effects of ZNS. The meta-analysis by
Chadwick and Marson [8] reported that the most
frequent adverse effects of ZNS treatment were
ataxia, dizziness, somnolence, nervousness, and
anorexia, indicating a predominance of cognitive
adverse effects. However, a recent study found no
differences betweenZNS- andVPA-treatedpatients
in the subjective perception of cognitive or
neuropsychiatric adverse effects [9].
In light of this, the present study was
designed to examine possible differences in
cognitive adverse effects between ZNS and VPA
as monotherapy in patients with IGE.
METHODS
Objectives
The main objective of this clinical investigation
was to compare the impact on cognition of
monotherapy with ZNS versus VPA in patients
with IGE.
Study Design
We conducted a comparative, descriptive,
observational, retrospective cohort study in
two groups of patients diagnosed with IGE and
treated with ZNS (ZNS group) or VPA (VPA
group) as monotherapy.
Patient Selection
The authors consecutively recruited 900
patients under treatment at the Epilepsy Unit
of the Torrecardenas Hospital. Inclusion criteria
were age [16 years, a diagnosis of IGE (any
variant) according to the diagnostic
recommendations of the International League
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Against Epilepsy (ILAE), stable and identifiable
antiepileptic treatment during the previous
6 months with VPA C1000 mg/day or ZNS
C200 mg/day as monotherapy, capacity to
provide clinical data required for the study
(according to the judgment of the researcher),
and written informed consent to participate in
the study. Exclusion criteria were the presence
of developmental delay, simultaneous treatment
with psychotropic drugs, or other factors that
could interfere with the neuropsychological
assessment (e.g., praxis-induced seizures during
the study or the presence of psychiatric
comorbidity that could affect the cognitive
evaluation).
Sample Size Calculation
No previous data were available for sample size
estimation. Given that the objective was to
compare cognitive adverse effects between two
treatments, and the imposition of strict
inclusion criteria, we aimed to enroll at least
eight patients in each group for a preliminary
comparison.
Selection of Variables
The following neuropsychological test battery
was used for cognitive evaluation in all
participants.
Laterality Test
Edinburgh Handedness Inventory [10] Subjects
evaluate the use of one or the other hand in
different basic activities of daily living using a
Likert-type scale (1 = right very preferential;
2 = right preferential; 3 = either hand equally;
4 = left preferential; 5 = left very preferential).
Short- and Long-Term Mnemonic Functions,
Working Memory, and Visuospatial Speed
Rey Verbal Memory (Rey Auditory Verbal Learning
Test and Rey Verbal Learning Test) [11] The
evaluator reads aloud a list of 15 words that
patients must subsequently repeat (in any
order); after subjects verbally recall all the
words they remember, the same list is read out
again. This procedure is repeated up to five
times; this part of the test assesses short-term
learning capacity and verbal memory and yields
a learning curve (RAVLT1). Next, subjects
undergo a distraction period of 20 min and are
then asked to say the words they remember
from the previously read list. This part evaluates
long-term memory and capacity to retain verbal
information (RAVLT2).
Forward and Backward Digit Span Test (WAIS-III)
[12] The WAIS-III evaluates the phonological
loop, concentration, and executive attention
and offers a measure of immediate verbal recall
and retention and the length of attention
span. The examiner reads aloud a series of
numbers, and the subject must repeat them,
first in the same order and then in inverse
order.
Rey–Osterrieth Complex Figure Test (ROCFT)
[13] This test evaluates visuoperceptual
construction and spatial memory through the
reproduction of a geometric figure. Subjects
must first produce a copy that is as identical as
possible while the duration of the task is
recorded. The picture is then removed and
subjects are asked to reproduce it from
memory. Finally, subjects undergo 20 min of
distracting tasks and must then reproduce the
figure from memory as accurately as possible,
leaving out no details. The test evaluates
copying capacity (ROCFT), memory (ROCFCP
test and ROCFLP test), and execution time
(ROCFT).
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Spatial Localization (WMS) [14] The WMS
evaluates visual span, visual working memory,
and concentration using a board with blocks
that are tapped by the examiner in a certain
order that the subject must immediately repeat
(forward Corsi block test). In a second test, the
subject must invert the order in which the
blocks are tapped by the examiner (backward
Corsi block test).
Test of Attention and Processing Speed
Trail-Making Test A and B [11] These are tests of
visual search speed, sustained and divided
attention, and cognitive flexibility. Subjects
are given a sheet with a series of disordered
numbers that they must join together as quickly
as possible without lifting the pen from the
paper (TMT-A). Subjects are then given another
sheet with disordered letters and numbers that
they must join together in an alternate manner
and in order as quickly as possible (TMT-B).
Stroop Test [15] This test measures processing
speed, selective attention, and inhibition. In the
first of three parts, subjects must read a series of
colors (blue, red, and green; Stroop-C test) as
quickly as possible. In the second part, they
must name the color of an X-shaped stimulus
that is presented (Stroop-P test). In the final
part, they are presented with the names of
colors written in a different color to that of their
name; subjects must name the color in which
the word is written, inhibiting its meaning
(Stroop-PC test).
Verbal Fluency Test and Executive Functions
Verbal Fluency Test (Phonetics and Semantics) [11]
This test yields information on semantic
memory, executive functions, and the capacity
of subjects to change tasks. Subjects are asked to
state in 1 min as many words as they can that
begin with ‘‘p’’. Next, they are asked to say in
1 min the names of all animals they can
remember, regardless of the first letter.
Zoo Map Test [16] This is included in the
Behavioral Assessment of Dysexecutive
Syndrome (BADS) by Alderman et al. It is a
planning test in which subjects must organize a
route around a zoo and visit 6 of 12 possible
localizations. In the first test, the route may be
planned freely with no restrictions, whereas
limitations are imposed in subsequent tests.
Visual Perception Test and Abstraction
Capacity
Blocks (WAIS-III) [12] This test yields
information on visual perception, capacity to
establish spatial relations, and visuomotor
coordination. Subjects are given (identical)
blocks with which they must reproduce a
figure drawn on paper as quickly as possible.
Similarities (WAIS-III) This test provides
information on the abstraction and reasoning
capacities of participants, who must identify
something that two apparently different
elements share in common.
Test of Anxiety, Depression, and Apathy
Hospital Anxiety and Depression Scale (HADS) This
test is a self-administered 14-item scale to
evaluate subjects’ mood (anxiety/depression).
Starkstein scale This test is a self-administered
14-item scale to evaluate subjects’ degree of
apathy.
Reference values were taken from normative
data in the Spanish NEURONORMA Project
[17].
We also gathered data from all participants
using a standardized data collection form,
including age (in years), sex, specific epilepsy
syndrome diagnosis, and number of seizures
during the previous 3 months. Data were
included in a global study database.
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Statistical Analysis
We expressed continuous variables as means
with standard deviations, medians, or range
(maximum and minimum values) according to
their distribution, and categorical variables as
frequencies and percentages. We applied the
Shapiro–Wilk or Kolmogorov–Smirnov test to
examine the distribution of the variables; the
Student’s t test or Mann–Whitney U test to
compare continuous variables between the
groups, as appropriate; and the Chi-squared
(v2) or exact Fisher tests to compare categorical
variables.
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
In total, 24 patients diagnosed with IGE by the
Epilepsy Unit of the Torreca´rdenas Hospital in
Almeria met the inclusion criteria. One patient
was excluded for severe depression considered
to affect cognitive performance, another for
praxis seizures during the cognitive
examination, and a further six patients could
not be contacted. Hence, the final sample
included 16 patients, eight under
stable treatment with VPA in monotherapy
(VPA group) and eight under treatment with
ZNS in monotherapy (ZNS group). Patients were
assigned to these groups before the study
according to clinical criteria alone.
Participants were aged between 16 and
60 years ( _x ¼ 31:74 years; standard deviation
10.47); eight were male and eight female;
56.25% had primary schooling, 12.5%
secondary schooling, and 31.25% higher/
university education. The mean number of
years of schooling was 12.88 years (standard
deviation 4.09; range 8–22). Patients from both
groups were seizure free in the 3 months prior
to the neuropsychological exploration.
Edinburgh Handedness Inventory results
showed right-hand laterality in 15 of the 16
participants and left-hand laterality in one
subject.
Subjective cognitive complaints were
reported by 68.75% of the sample, described as
difficulties in attention (12.5%), memory
(12.5%), or memory and attention (37.5%),
and disorientation (6.25%).
The epilepsy diagnosis was IGE with isolated
tonic–clonic seizures in nine patients, Janz
juvenile myoclonic epilepsy (JME) in five,
childhood absence epilepsy (CAE) in one, and
juvenile absence epilepsy (JAE) in another.
As shown in Table 1, the two groups did not
significantly differ in any demographic or
clinical variable except that the ZNS group had
more females and the VPA group had more
males.
Tables 2, 3, 4, 5, and 6 exhibit the bivariate
comparison of the test battery results.
Significantly superior mean scores were
obtained by the VPA (vs. ZNS) group in
working memory (forward digits test) and by
the ZNS group in execution time for the
Rey–Osterrieth complex figure test. No
statistically significant differences were found
between the groups in the remaining tests.
DISCUSSION
This study found no significant differences in
cognitive performance between patients with
IGE treated with VPA or ZNS as monotherapy,
indicating that the treatment decision can be
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individualized according to effectiveness
criteria or other types of adverse effect.
Although VPA is the AED of choice in most
clinical practice guidelines for IGE, it is
associated with teratogenic and adverse esthetic
effects (obesity, hirsutism, alopecia) that have an
especially negative impact in young women [18,
19]. An increased risk of autismhas been reported
in the children of epileptic mothers exposed to
VPA during pregnancy [20]. Calls for an
alternative to VPA [21] have intensified
following the recent ILAE recommendation
that this drug not be administered to girls or
women of childbearing age [22]. ZNS may be a
good alternative option in this patient
population given its wide action spectrum,
including different types of generalized
seizures, and its favorable profile of esthetic
adverse effects [4]. Nevertheless, perhaps due to
certain similarities with topiramate (TPM), ZNS
has been considered to have a worse cognitive
profile than VPA, despite the absence of studies
directly comparing these AEDs. This has
contributed to limited administration in
patients with IGE because of the important
impact of adverse cognitive effects on quality of
life [23].
A review of the efficacy and safety of ZNS in
combined therapy for focal epilepsy
demonstrated a good long-term cognitive
tolerability profile [24], whereas a study of
patients treated with ZNS, TPM, or
levetiracetam for alcohol abuse disorder
observed superior cognitive performance in
ZNS-treated versus TPM-treated patients,
mainly in relation to processing speed [25].
However, a recent prospective study in 14
patients with different types of epilepsy found
that ZNS treatment impaired performance in
memory, attention (TMT A and B), and verbal
fluency tests in a dose-dependent manner and
that these effects were sustained over time [26].
Hence, published research on the cognitive
impact of ZNS is scarce and results controversial.
Although VPA has been commercially
available for many years and is widely used in
epilepsy treatment, few data have been
published on its possible adverse cognitive
effects. Meador et al. [27] compared the side
effects of phenobarbital (PB), phenytoin (PHT),
Table 1 Between-group comparison of demographic data
Variable VPA group ZNS group P value
Age (years) 32.63 30.87 NS*
Male/female (%) 7/1 (87.5/12.5%) 1/7 (12.5/87.5%) 0.01**
Years of schooling 14.25 11.5 NS*
Subjective memory complaints (no/yes) 3/5 (37.5/62.5%) 2/6 (25/75%) NS**







Mean number of generalized seizures during previous 3 months 0 0 NS**
CAE childhood absence epilepsy, JAE juvenile absence epilepsy, JME juvenile myoclonic epilepsy, NS non-signiﬁcant, TCGS
isolated tonic–clonic generalized seizures, VPA valproic acid, ZNS zonisamide
* Student’s t test for quantitative variables
** Fisher’s exact test for categorical variables
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and VPA and only observed a worse cognitive
performance in the PB group, with no
differences between the PHT and VPA groups.
The same group found that cognitive adverse
effects were slightly worse with TPM than with
VPA [28], and TPM is known to be associated
with a poor neuropsychological profile [29].
Table 2 Between-group comparison of results in
mnemonic tests and working memory
Variable VPA group ZNS group P
RAVLT1 5.88 (1.55) 6.63 (1.59) NS
RAVLT2 11.88 (1.96) 12.13 (2.74) NS
RVLT 10.25 (3.06) 10.50 (2.97) NS
FD 8.63 (3.33) 5.13 (2.85) 0.04*
BD 9.25 (1.91) 7.50 (0.75) NS
ROCF 12.25 (3.24) 9.50 (3.66) NS
ROCFT 8 (2.62) 13.25 (5.42) 0.05*
ROCFST 9.38 (3.02) 10.75 (1.28) NS
ROCFLT 8.50 (3.81) 11.13 (2.03) NS
CORSI-F 9.13 (4.55) 6.63 (2.38) NS
CORSI-B 9.63 (3.20) 7.88 (2.95) NS
Data are presented as mean (standard deviation)
BD backward digits, CORSI-B backward Corsi block test,
CORSI-F forward Corsi block test, FD forward digits, NS
non-signiﬁcant, RAVLT Rey Auditory Verbal Learning
Test, ROCF Rey–Osterrieth complex ﬁgure, ROCFLT
long-term memory of Rey–Osterrieth complex ﬁgure,
ROCFST short-term memory of Rey-Osterrieth complex
ﬁgure, ROCFT execution time of the direct copy of
Rey-Osterrieth complex ﬁgure, RVLT Rey Verbal Learning
Test, VPA valproic acid, ZNS zonisamide
* Mann–Whitney U test
Table 3 Between-group comparison of attention and
processing speed test results
Variable VPA group ZNS group P value
TMT-A 8.13 (3.39) 6 (4.14) NS
TMT-B 6.38 (3.58) 6 (3.62) NS
Stroop-C 9.13 (2.64) 7.38 (3.16) NS
Stroop-P 6.75 (3.49) 7.38 (4.07) NS
Stroop-PC 8.13 (4.01) 7.38 (3.89) NS
Data are presented as mean (standard deviation)
NS non-signiﬁcant, TMT Trail Making Test, VPA
valproic acid, ZNS zonisamide
Table 6 Between-group comparison of results in anxiety,
depression, and apathy tests
Variable VPA group ZNS group P value
HADS anxiety 2 (4.50) 1.38 (1.40) NS
HADS depression 0.38 (1.06) 0.38 (1.06) NS
Starkstein scale 1.75 (3.28) 1.25 (1.39) NS
Data are presented as mean (standard deviation)
HADS Hospital Anxiety and Depression Scale, NS
non-signiﬁcant, VPA valproic acid, ZNS zonisamide
Table 4 Between-group comparison of verbal ﬂuency and
executive function test results
Variable VPA group ZNS group P value
Animals 5 (2.77) 5 (1.77) NS
P Word test 6.88 (3.31) 6.38 (2.50) NS
Zoo Map test 2.50 (0.53) 2.75 (0.46) NS
Data are presented as mean (standard deviation)
NS non-signiﬁcant, VPA valproic acid, ZNS zonisamide
Table 5 Between-group comparison of results in visual
perception and abstraction capacity tests
Variable VPA group ZNS group P value
Blocks
WAIS-III
8 (1.92) 6.63 (2.38) NS
Similarities
WAIS-III
9.13 (3.13) 10.75 (3.49) NS
Data are presented as mean (standard deviation)
NS non-signiﬁcant, VPA valproic acid, ZNS zonisamide
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To the best of our knowledge, our study is
the first to directly compare cognitive function
between IGE patients treated with VPA or ZNS
in real-life settings, applying tests of cognitive
performance in mnemonic capacity (including
working memory, verbal material, and visual
material memory), verbal fluency, executive
functions, visual perception, abstraction
capacity, visuospatial praxis, attention, and
processing speed, as well as tests evaluating
depression, anxiety, and apathy.
The iatrogenic cognitive adverse effect
profile of AEDs conventionally corresponds to
a reduction in attention level and processing
speed, with a possible impact on memory and
verbal fluency, while other cortical functions
are relatively unaffected [30]. In the present
study, no significant differences were found
between VPA and ZNS monotherapy in most
variables related to iatrogenic cognitive
dysfunction, indicating that cognitive
performance is no more greatly impaired by
ZNS than by VPA. For this reason, ZNS may be a
reasonable alternative to VPA in patients with
IGE. This message is reinforced by the
observation that ZNS showed good efficacy
and tolerability in the treatment of myoclonic
seizures in patients with progressive myoclonic
epilepsy [31].
In terms of the visuospatial praxis, both
groups showed a similar execution capacity in
the ROCFT, but the ZNS group completed it
more quickly. These results are interpreted as
indicating a superior performance by the ZNS
group in complex praxis, i.e., in purely cortical
domains.
The VPA group achieved better results (vs. the
ZNS group) in the Forward Digit test, which
evaluates sustained attention and concentration
capacity, whereas no between-group differences
were found in the Backward Digit test, which is
more closely related to working memory,
attention control, and executive attention.
These findings may indicate a slightly worse
selective attention or concentration in
ZNS-treated patients, with no differences
between groups in executive attention.
However, no significant between-group
differences were found in other attention tests
(e.g., Trail-Making or Stroop Tests).
The only significant difference in baseline
clinical and demographic variables (see Table 1)
was in sex. The higher proportion of females in
theZNSgroup (87.5%vs. 12.5%) is attributable to
the ILAE recommendations that VPA should be
avoided in young women. Nevertheless, this
cannot be considered a study bias, because
sex is not expected to influence cognitive
performance in the studied tasks.
The main limitations of this study are the
small sample size, caused by our strict
inclusion criteria, and the absence of a
baseline cognitive assessment, which would
be ideal for the goal that we pursue.
However, this is not ethically feasible in
clinical practice as it would mean a delay in
the start of treatment. On the other hand, it is
possible that our study excluded patients with
severe cognitive side effects that have not
reach 6 months of treatment. However, the
analysis of the published series shows no
significant difference in retention rates
between the two molecules [32, 33].
As this is the first study to directly compare
the cognitive profile of the two monotherapies
in real-life settings, other studies may be needed
to confirm and refine our results.
CONCLUSIONS
Zonisamide as monotherapy has a similar
cognitive profile to that of VPA in patients
with IGE. The final treatment selection setting
should be individualized. In terms of cognitive
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performance, there appears to be no reason to
select one drug over the other, and the decision
should be based on individual effectiveness,
comorbidities, and somatic or esthetic adverse
effects.
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